Related Experiment Video

Updated: Jun 13, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]

A Fléchon1, H Boyle, S Négrier

  • 1Centre Léon-Bérard, Université de Lyon, Département d'oncologie médicale, 28, rue Laennec, 69008 Lyon, France. flechon@lyon.fnclcc.fr

Bulletin Du Cancer
|April 27, 2010
PubMed

Insights

New antiangiogenic agents have transformed renal cell carcinoma treatment, but managing their side effects is crucial for patient compliance and quality of life. This report details adverse events and management strategies for these innovative therapies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Antiangiogenic agents have recently revolutionized renal cell carcinoma (RCC) management.
  • Four such drugs (sorafenib, sunitinib, bevacizumab, temsirolimus) are approved in France for advanced or metastatic RCC.
  • A fifth agent, everolimus, is anticipated.

Purpose of the Study:

  • To detail the adverse events associated with different classes of antiangiogenic agents used in RCC.
  • To provide guidance on managing the side effects of these novel therapies.

Main Methods:

  • Review of adverse events linked to specific antiangiogenic drug classes.
  • Description of management strategies for identified toxicities.

Main Results:

  • Sorafenib, sunitinib, bevacizumab, and temsirolimus are associated with distinct adverse event profiles.
  • Effective management of these side effects is essential for treatment adherence.

Conclusions:

  • The advent of antiangiogenic agents necessitates a thorough understanding of their associated toxicities.
  • Proactive management of adverse events is critical for optimizing patient outcomes and quality of life in advanced RCC.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...